Source: PR Newswire

Press Release: Morphotek : Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium

EXTON, Pa., Jan. 24, 2018 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present the following poster at the ASCO-SITC Clinical Immuno-oncology Symposium being held at the Marriott Marquis in San Francisco, CA from January 25-27, 2018:...

Read full article »
Morphotek's Competitors | Morphotek's News | Morphotek's Financials

March 18, 2023

Cision Canada

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

/CNW/ - Summary Product: Gilead Sciences, Inc., Cayston (Lots 032168 and 033357) Issue: Health produc... See more »

March 18, 2023

GlobalNewswire

Press Release: Dupixent (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms o... See more »

March 18, 2023

Cision Canada

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

/CNW/ - Summary Product: Gilead Sciences, Inc., Cayston (Lots 032168 and 033357) Issue: Health produc... See more »

March 18, 2023

GlobalNewswire

Press Release: Dupixent (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms o... See more »
Stay up-to-date with the latest news on Morphotek
Est. Annual Revenue
$25-100M
Agree?
Est. Employees
25-100
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Morphotek